<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Regular blood transfusions as supportive care for patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001903'>anemia</z:hpo> inevitably lead to <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> as humans cannot actively remove excess iron </plain></SENT>
<SENT sid="1" pm="."><plain>The cumulative effects of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> cause significant morbidity and mortality if not effectively treated with chelation therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Based on a comprehensive clinical development program, the once-daily, oral iron <z:chebi fb="0" ids="38161">chelator</z:chebi> <z:chebi fb="0" ids="49005">deferasirox</z:chebi> (<z:chebi fb="0" ids="49005">Exjade</z:chebi>((R))) is approved for the treatment of transfusional <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in adult and pediatric patients with various transfusion-dependent <z:hpo ids='HP_0001903'>anemias</z:hpo>, including <z:e sem="disease" ids="C0005283" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia</z:e> and the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> dose should be titrated for each individual patient based on transfusional iron intake, current iron burden and whether the goal is to decrease or maintain body iron levels </plain></SENT>
<SENT sid="4" pm="."><plain>Doses of &gt;30 mg/kg/day have been shown to be effective with a safety profile consistent with that observed at doses &lt;30 mg/kg/day </plain></SENT>
<SENT sid="5" pm="."><plain>Recent data have highlighted the ability of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> to decrease cardiac iron levels and to prevent the accumulation of iron in the heart </plain></SENT>
<SENT sid="6" pm="."><plain>The long-term efficacy and safety of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> for up to 5 years of treatment have now been established </plain></SENT>
<SENT sid="7" pm="."><plain>The availability of this effective and generally well tolerated oral therapy represents a significant advance in the management of transfusional <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
</text></document>